MTOR and acute myeloid leukemia: In this study, elevated in vitro efficacies were detected in the combination treatments of venetoclax with BH3 mimetics A1331852 and S63845 and the dual PI3K-mTOR inhibitor bimiralisib, in AML with elevated blast cell percentage, at drug concentrations that can be reached in vivo in the plasma, with different response markers in each combination.